Neurocrine Bio. (NBIX) PT Lowered to $136 at Stifel, Ingrezza's Growth and Sales, and Pipeline Prospects Remain Key Focus for Investors,

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. CRWV
8. MSFT
9. MH
10. DLMAF

Go back to Neurocrine Bio. (NBIX) PT Lowered to $136 at Stifel, Ingrezza's Growth and Sales, and Pipeline Prospects Remain Key Focus for Investors,

Neurocrine Bio. (NBIX) PT Lowered to $150 at Oppenheimer

February 14, 2022 8:30 AM EST

Oppenheimer analyst Jay Olson lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $150.00 (from $154.00) while maintaining an Outperform rating.

The analyst commented, "NBIX shares have outperformed in 2022 (+7% vs. NBI -14% and S&P 500 -7% YTD) based on a favorable setup that... More